$RDGL
VIVOS INC

2022 Q4 Form 10-Q Financial Statement

#000149315222028874 Filed on October 19, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $6.500K $6.500K $14.89K
YoY Change -56.35% 112.71%
Cost Of Revenue $10.73K $13.04K $6.000K
YoY Change -10.58% 117.25%
Gross Profit -$4.230K -$6.535K $8.887K
YoY Change -64.75% -173.53%
Gross Profit Margin -65.08% -100.54% 59.68%
Selling, General & Admin $669.7K $199.8K $142.6K
YoY Change 356.35% 40.05% 17.83%
% of Gross Profit 1605.04%
Research & Development $31.74K $70.77K $66.83K
YoY Change -46.83% 5.89% 364.74%
% of Gross Profit 752.0%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $701.4K $270.5K $209.5K
YoY Change 239.77% 29.15% 54.66%
Operating Profit -$705.6K -$277.1K -$194.6K
YoY Change 223.04% 42.39%
Interest Expense $0.00 -$6.580K
YoY Change -100.0% -7.97%
% of Operating Profit
Other Income/Expense, Net $0.00
YoY Change
Pretax Income -$705.7K -$277.1K -$201.2K
YoY Change 295.92% 37.73% 48.36%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$705.7K -$277.1K -$201.2K
YoY Change 295.92% 37.73% 48.36%
Net Earnings / Revenue -10856.15% -4262.54% -1350.97%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 -$772.30 -$599.60
COMMON SHARES
Basic Shares Outstanding 359.9M shares 358.9M shares 335.5M shares
Diluted Shares Outstanding 343.9M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.706M $1.988M $1.987M
YoY Change 6.22% 0.06% 13206.03%
Cash & Equivalents $1.706M $1.988M $1.987M
Short-Term Investments
Other Short-Term Assets $25.67K $45.42K $48.32K
YoY Change -8.91% -6.0% 12.45%
Inventory
Prepaid Expenses $25.67K $45.42K
Receivables $11.00K $13.00K $8.890K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.743M $2.046M $2.044M
YoY Change 6.64% 0.12% 3429.86%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.743M $2.046M $2.044M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $1.743M $2.046M $2.044M
YoY Change 6.64% 0.12% 3429.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $81.69K $161.0K $172.7K
YoY Change -51.06% -6.78% -54.26%
Accrued Expenses $118.9K
YoY Change -47.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $295.8K
YoY Change -100.0% 0.61%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $81.69K $161.0K $619.4K
YoY Change -51.06% -74.01% -33.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $81.69K $161.0K $619.4K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $81.69K $161.0K $619.4K
YoY Change -51.06% -74.01% -33.27%
SHAREHOLDERS EQUITY
Retained Earnings -$79.56M -$78.85M
YoY Change 3.2%
Common Stock $71.58M $71.10M
YoY Change 3.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.661M $1.885M $1.424M
YoY Change
Total Liabilities & Shareholders Equity $1.743M $2.046M $2.044M
YoY Change 6.64% 0.12% 3429.86%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$705.7K -$277.1K -$201.2K
YoY Change 295.92% 37.73% 48.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$281.7K -$283.0K -$178.1K
YoY Change 19.62% 58.9% -3.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.220M 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -281.7K -283.0K -178.1K
Cash From Investing Activities
Cash From Financing Activities 0.000 1.220M 0.000
Net Change In Cash -281.7K 937.0K -178.1K
YoY Change -25.97% -626.18% -23.87%
FREE CASH FLOW
Cash From Operating Activities -$281.7K -$283.0K -$178.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Interest Expense
InterestExpense
usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
usd
CY2021Q3 RDGL Forgiveness Of Debt
ForgivenessOfDebt
usd
RDGL Forgiveness Of Debt
ForgivenessOfDebt
usd
CY2022Q3 RDGL Forgiveness Of Debt
ForgivenessOfDebt
usd
dei City Area Code
CityAreaCode
(509)
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2021Q1 RDGL Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
usd
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
usd
CY2021Q3 RDGL Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
usd
CY2022Q1 RDGL Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
usd
CY2022Q3 RDGL Stock Issued During Period Value Fractional Adjustment
StockIssuedDuringPeriodValueFractionalAdjustment
usd
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Central Index Key
EntityCentralIndexKey
0001449349
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
99352
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
RDGL Forgiveness Of Debt
ForgivenessOfDebt
usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
RDGL Conversion Of Notes Payable Related Parties And Accrued Interest Into Common Stock
ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock
usd
RDGL Rsus Vested Into Common Stock
RsusVestedIntoCommonStock
usd
RDGL Stock Options Exercised For Recission Of Common And Preferred Stock
StockOptionsExercisedForRecissionOfCommonAndPreferredStock
usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021 RDGL Weighted Average Exercise Price Per Share Options Granted
WeightedAverageExercisePricePerShareOptionsGranted
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021 RDGL Weighted Average Exercise Price Per Share Options Exercised
WeightedAverageExercisePricePerShareOptionsExercised
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021 RDGL Weighted Average Exercise Price Per Share Options Expired
WeightedAverageExercisePricePerShareOptionsExpired
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
RDGL Weighted Average Exercise Price Per Share Options Granted
WeightedAverageExercisePricePerShareOptionsGranted
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
RDGL Weighted Average Exercise Price Per Share Options Exercised
WeightedAverageExercisePricePerShareOptionsExercised
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
RDGL Weighted Average Exercise Price Per Share Options Expired
WeightedAverageExercisePricePerShareOptionsExpired
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53497
dei Entity Registrant Name
EntityRegistrantName
VIVOS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
80-0138937
dei Entity Address Address Line1
EntityAddressAddressLine1
719 Jadwin Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Richland
dei Local Phone Number
LocalPhoneNumber
736-4000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
359891255 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1987732 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1606123 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13000 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
45418 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
28175 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
2046150 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1634298 usd
CY2022Q3 us-gaap Assets
Assets
2046150 usd
CY2021Q4 us-gaap Assets
Assets
1634298 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
160953 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
166915 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
160953 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
166915 usd
CY2022Q3 us-gaap Liabilities
Liabilities
160953 usd
CY2021Q4 us-gaap Liabilities
Liabilities
166915 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
359891255 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
359891255 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
343530678 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
343530678 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
359891 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
343531 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
70739104 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
68573142 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78850375 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77085867 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1885197 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1467383 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2046150 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1634298 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14887 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6500 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14887 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18053 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13035 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6000 usd
us-gaap Gross Profit
GrossProfit
11947 usd
us-gaap Gross Profit
GrossProfit
8887 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
-6535 usd
CY2021Q3 us-gaap Gross Profit
GrossProfit
8887 usd
us-gaap Professional Fees
ProfessionalFees
1191807 usd
us-gaap Professional Fees
ProfessionalFees
1786028 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
93300 usd
CY2021Q3 us-gaap Professional Fees
ProfessionalFees
55583 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
208818 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
202428 usd
CY2022Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
68163 usd
CY2021Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
64925 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
312066 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
221154 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70765 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60831 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
111352 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
82635 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38302 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22131 usd
us-gaap Operating Expenses
OperatingExpenses
1824043 usd
us-gaap Operating Expenses
OperatingExpenses
2292245 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
270530 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
203470 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1812096 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2283358 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-277065 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-194583 usd
us-gaap Interest Expense
InterestExpense
19628 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
6577 usd
RDGL Forgiveness Of Debt
ForgivenessOfDebt
129745 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
47588 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-176295 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47588 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-66178 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6577 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1764508 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2349536 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-277065 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-201160 usd
us-gaap Net Income Loss
NetIncomeLoss
-1764508 usd
us-gaap Net Income Loss
NetIncomeLoss
-2349536 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-277065 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-201160 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
348563383 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
321548977 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
358750041 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
335506200 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32034 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1800000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
226665 usd
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
50000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
11238 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-288189 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1831748 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
40000 usd
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1614000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1860187 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
1625561 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-201160 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
1424401 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1467383 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4880 usd
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
450000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-699905 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1222358 usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
458200 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-787538 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
893020 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
893020 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1200000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
49242 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
20000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-277065 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1885197 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1885197 usd
us-gaap Net Income Loss
NetIncomeLoss
-1764508 usd
us-gaap Net Income Loss
NetIncomeLoss
-2349536 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
4880 usd
RDGL Restricted Stock Units Issued For Services
RestrictedStockUnitsIssuedForServices
908200 usd
RDGL Restricted Stock Units Issued For Services
RestrictedStockUnitsIssuedForServices
1614000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
47588 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-176295 usd
RDGL Forgiveness Of Debt
ForgivenessOfDebt
129745 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8887 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17243 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14480 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
90868 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
30517 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-66143 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
19628 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
926117 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1621185 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-838391 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-728351 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1220000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1811238 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1220000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1811238 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
381609 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1082887 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1606123 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
903704 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1987732 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1986591 usd
RDGL Conversion Of Notes Payable Related Parties And Accrued Interest Into Common Stock
ConversionOfNotesPayableRelatedPartiesAndAccruedInterestIntoCommonStock
50370 usd
us-gaap Stock Issued1
StockIssued1
300 usd
us-gaap Stock Issued1
StockIssued1
4708 usd
RDGL Rsus Vested Into Common Stock
RsusVestedIntoCommonStock
12000 usd
RDGL Accounts Payable Converted Into Shares Of Common Stock
AccountsPayableConvertedIntoSharesOfCommonStock
49242 usd
RDGL Accounts Payable Converted Into Shares Of Common Stock
AccountsPayableConvertedIntoSharesOfCommonStock
90000 usd
RDGL Stock Options Exercised For Recission Of Common And Preferred Stock
StockOptionsExercisedForRecissionOfCommonAndPreferredStock
60000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Description Of Credit Risk Exposure
DescriptionOfCreditRiskExposure
half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2500000 usd
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
50000000 shares
CY2021Q3 us-gaap Share Price
SharePrice
0.10
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1200000 usd
CY2022Q3 us-gaap Share Price
SharePrice
0.08
CY2022Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
15000000 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
20000000 shares
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
20000 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2500000 usd
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1661429 usd
CY2020Q4 RDGL Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice
0.05
RDGL Offering Term
OfferingTerm
Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials, (2) conduct Phase I, pilot, clinical trials, (3) activate several regional clinics to administer IsoPet® across the county, (4) create an independent production center within the current production site to create a template for future international manufacturing, and (5) initiate regulatory approval processes outside of the United States
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1987732 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_843_eus-gaap--UseOfEstimates_zKJTHdRBKdUd" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates the Company considers include criteria for stock-based compensation expense, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_845_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zti1q4fzwVx5" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statement Reclassification</b></span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain account balances from prior periods have been reclassified in these financial statements so as to conform to current period classifications.</span></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Production Costs
ProductionCosts
2500 usd
CY2022Q3 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
1500 usd
CY2022Q3 us-gaap Indefinite Lived License Agreements
IndefiniteLivedLicenseAgreements
4000 usd
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
359891255 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
343530678 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
343530678 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
87562379 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
69287379 shares
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2500000 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
24132652 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2252809 shares
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
83992 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
312066 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
221154 usd
CY2021Q4 RDGL Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice
0.04
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2252809 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30901 usd
CY2022Q3 RDGL Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePrice
0.04
CY2021Q4 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
237000 usd
CY2020Q4 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
237000 usd
CY2022Q3 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
0 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
0 usd
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
950000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
359891255 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 RDGL Functional Adjustment Shares
FunctionalAdjustmentShares
90 shares
CY2022Q3 us-gaap Share Price
SharePrice
0.08
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
20000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-176295 usd
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1800000 usd
CY2021Q1 RDGL Warrant Purchase
WarrantPurchase
11238 usd
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
28885461 shares
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M25D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2252809 shares
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y11M12D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
30901 usd
CY2022Q3 RDGL Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Per Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePerShares
0.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.66 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.03 pure
us-gaap Restricted Stock Expense
RestrictedStockExpense
908200 usd
us-gaap Restricted Stock Expense
RestrictedStockExpense
1614000 usd
RDGL Restricted Stock Expenses Yet To Be Recognized
RestrictedStockExpensesYetToBeRecognized
1505400 usd

Files In Submission

Name View Source Status
0001493152-22-028874-index-headers.html Edgar Link pending
0001493152-22-028874-index.html Edgar Link pending
0001493152-22-028874.txt Edgar Link pending
0001493152-22-028874-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rdgl-20220930.xsd Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
rdgl-20220930_cal.xml Edgar Link unprocessable
rdgl-20220930_lab.xml Edgar Link unprocessable
rdgl-20220930_def.xml Edgar Link unprocessable
rdgl-20220930_pre.xml Edgar Link unprocessable